文献速递血管炎

Avacopan与ANCA相关血管炎严重感染风险降低:REVEAL多中心队列的时变暴露建模

Reduced severe infection risk with avacopan in ANCA-associated vasculitis: a multicentre REVEAL cohort with time-varying exposure modelling.
PubMed 文献 · Rheumatology (Oxford) · 2026-01-01

本研究为多中心回顾性队列,纳入387例ANCA相关血管炎患者,其中52例接受Avacopan(AVA)、335例未接受,采用时变暴露建模和稳定逆概率治疗加权分析。结果显示AVA暴露与严重感染估计风险降低相关(校正HR 0.22,95%CI 0.07-0.68;P=0.008),复发风险无统计学显著差异,且AVA使用与随时间降低的泼尼松龙暴露相关。

要点

  • AVA暴露与严重感染估计风险降低相关,校正HR 0.22(95%CI 0.07-0.68;P=0.008)。
  • AVA暴露与复发性复发风险无统计学显著差异。
  • AVA使用与随时间降低的泼尼松龙暴露相关,糖皮质激素校正模型方向一致但幅度随模型设定变化。

核心结论

  • 在多中心真实世界队列中,AVA暴露与严重感染估计风险降低及糖皮质激素暴露减少相关,但复发性复发风险无统计学显著降低。
  • 观察性设计限制因果推断,AVA治疗方案可能与常规实践中感染相关结局改善相关。

研究设计与样本

  • 多中心回顾性队列研究,AVA使用建模为时变暴露,采用稳定逆概率治疗加权校正基线差异。
  • 共纳入387例ANCA相关血管炎患者,其中52例接受AVA、335例未接受。
  • 复发性复发和严重感染(定义为需住院的感染)采用基于Andersen-Gill公式的时依Cox比例风险模型分析。

主要发现

  • AVA暴露与严重感染估计风险降低相关(校正HR 0.22,95%CI 0.07-0.68;P=0.008)。
  • AVA暴露与复发性复发风险无统计学显著差异。
  • AVA使用与随时间降低的泼尼松龙暴露相关。
  • 在糖皮质激素校正模型中,AVA与严重感染的关联方向一致,但幅度随模型设定变化。

临床怎么用

  • 在ANCA相关血管炎常规实践中,含AVA的治疗策略可能与感染相关结局改善相关。
  • AVA使用可能有助于减少糖皮质激素暴露。
  • 因观察性设计,不能从本研究推断AVA与感染风险降低的因果关系。

局限性

  • 观察性设计 preclude 因果推断。
  • AVA暴露与严重感染的关联幅度随模型设定变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the association between avacopan (AVA) use and recurrent relapse and severe infection in patients with ANCA-associated vasculitis, with particular attention to time-varying treatment and glucocorticoid (GC) exposure. METHODS: In this multicentre retrospective cohort study, AVA use was modelled as a time-varying exposure. Stabilized inverse probability of treatment weighting was used to adjust for baseline differences. Recurrent relapse and severe infection, defined as an infection requiring hospitalization, were analysed using time-dependent Cox proportional hazards models based on the Andersen-Gill formulation. Exploratory models additionally incorporated time-varying and cumulative prednisolone exposure. RESULTS: A total of 387 patients were included, of whom 52 received AVA and 335 did not. AVA exposure was associated with a lower estimated risk of severe infection (adjusted HR 0.22, 95% CI 0.07-0.68; P = 0.008), whereas no statistically significant difference in recurrent relapse risk was observed. AVA use was also associated with lower prednisolone exposure over time. This association with severe infection remained directionally consistent in GC-adjusted models, although its magnitude varied depending on model specification. CONCLUSION: In this multicentre real-world cohort, AVA exposure was associated with a lower estimated risk of severe infection and reduced GC exposure, whereas no statistically significant reduction in recurrent relapse risk was observed. These findings suggest that an AVA-containing treatment strategy may be associated with improved infection-related outcomes in routine practice, although the observational design precludes causal inference.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Yoshida T, Hiwa R, Shoji M, et al. Reduced severe infection risk with avacopan in ANCA-associated vasculitis: a multicentre REVEAL cohort with time-varying exposure modelling. Rheumatology (Oxford). 2026. PMID: 42757695. doi:10.1093/rheumatology/keag517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。